The Economic Times

Moderna shares up 2% as skin cancer vaccine shows sustained benefit in five-year follow-up

Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of the most deadly skin cancer five years after the treatment started.